Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04904757
Other study ID # IRB#18853
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 19, 2019
Est. completion date June 2023

Study information

Verified date November 2022
Source University of Virginia
Contact Kathy L Repich, RN
Phone 4342434540
Email klr3b@virginia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.


Description:

Contrast-enhanced spectral mammography (CESM) is an FDA approved tool for breast cancer detection. However, adoption into clinical practice has been slow. In this study, we will explore patient issues related to the use of CESM for breast cancer screening. For this study, 210 women with heterogeneous or dense breast tissue reported on a previous mammogram, will be recruited to undergo a screening Contrast-enhanced Spectral Mammography (CESM). The CESM will serve as the subject's annual screening breast exam for clinical care. A survey will be administered before and after the examination that evaluates the patient experience. Women will not be at high risk for breast cancer (<20% lifetime risk). All abnormal findings will be acted upon independently. Results of the general screening population survey will be compared with those of women who choose to undergo the CESM examination in order to evaluate the influence of age, education, and lifetime risk on decision making about advanced screening.


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date June 2023
Est. primary completion date December 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 69 Years
Eligibility Inclusion Criteria: - • Female - 40 to 69 years - Previous normal mammogram (BI-RADS 1 or 2) showing heterogeneous or extremely dense breast tissue within last 24 months - Scheduled for screening mammogram as part of the patient's clinical care Exclusion Criteria: - • No mammogram within last 24 months - Fatty or scattered fibroglandular tissue on last mammogram - History of allergy to iodinated contrast - History of renal disease or renal function abnormalities - Pregnant women - History of diabetes - History of paraproteinemia syndromes such as multiple myeloma - History of collagen vascular disease - History of vascular disease (coronary artery disease, myocardial infarction, carotid disease, peripheral vascular disease, or known visceral artery disease) - Previously identified as high risk for breast cancer (>20% lifetime risk) - Asthma - Sickle Cell Anemia - Currently on Dialysis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Contrast-enhanced spectral mammography (CESM)
CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.

Locations

Country Name City State
United States UVA Breast Care Center Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the patient experience during a screening CESM Plan for primary variable analysis: To evaluate the patient experience during a screening CESM to better understand if women find the experience of contrast injection to be too invasive or unpleasant to repeat or recommend to a friend.
Data summarization: Pre and post CESM survey responses that are binary or Likert scaled responses will be summarized by frequencies and percentages. Pre and post CESM survey responses that are continuous scaled responses will be summarized by the mean and standard deviation, the median and interquartile range, and the range of distribution.
16 months
Secondary determine if there is an association between the willingness to undergo CESM and age, level of education, and breast cancer related risk factors. We will evaluate differences by age, education, and risk factors as to whether these drive willingness to undergo CESM.
Data summarization: Binary risk factors will be summarized by frequencies and percentages. Continuous scaled risk factors will be summarized by the mean and standard deviation, the median and interquartile range, and the range of distribution.
16months
See also
  Status Clinical Trial Phase
Recruiting NCT04983875 - Mammography and Breast Arterial Calcification: An Information-Sharing Trial N/A
Recruiting NCT05975736 - Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening N/A
Withdrawn NCT03639129 - Improving Characterization of Calcifications With Contrast-Enhanced Mammography N/A
Completed NCT03684733 - Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer
Completed NCT00827307 - Zoladex Plus Tamoxifen in Breast Cancer N/A
Completed NCT00724516 - Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography N/A
Not yet recruiting NCT06469606 - Study on Female Patients' Mammographic Texture Features N/A
Completed NCT04009278 - Self-compression Mammography in Clinical Practice N/A
Completed NCT01124019 - Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
Recruiting NCT03857152 - Can Contrast Enhanced Spectral Mammography (CESM) Reduce the Number of Benign Biopsies for Calcifications Without Negatively Impacting on Detection/Diagnosis of Clinically Significant Calcifications N/A
Recruiting NCT05199701 - Prospective Case Collection Study for New Mammography Technologies N/A
Recruiting NCT05009277 - Study To Evaluate The Sensitivity Of The Linda Thermal Device
Completed NCT04741503 - Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool N/A
Not yet recruiting NCT06265207 - The Effect of Virtual Reality on Pain, Anxiety and Satisfaction Level Before Mammography N/A